Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Maria Mareque, Pau Montesinos, Patricia Font, José María Guinea, Adolfo de la Fuente, Javier Soto, Itziar Oyagüez, James Brockbank, Tamara Iglesias, Julia Llinares & Jorge Sierra. (2021) Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain. ClinicoEconomics and Outcomes Research 13, pages 263-277.
Read now
Read now
Anil Wagh, Hangtian Song, Ming Zeng, Li Tao & Tapan K. Das. (2018) Challenges and new frontiers in analytical characterization of antibody-drug conjugates. mAbs 10:2, pages 222-243.
Read now
Read now
Articles from other publishers (37)
Sofía Huerga-Domínguez, Sara Villar, Felipe Prósper & Ana Alfonso-Piérola. (2022) Updates on the Management of Acute Myeloid Leukemia. Cancers 14:19, pages 4756.
Crossref
Crossref
M. Bill & C. Röllig. (2022) Standards der kurativen Systemtherapie der akuten myeloischen LeukämieCurrent standards for a curative treatment of acute myeloid leukemia. Die Onkologie 28:6, pages 474-482.
Crossref
Crossref
Yue Huang, Mi Shao, Yiyun Wang & He Huang. (2022) Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives. ImmunoMedicine 2:1.
Crossref
Crossref
Yi Liu, Sanmei Wang, Maria‐Luisa Schubert, Annika Lauk, Hao Yao, Maximilian Felix Blank, Chunhong Cui, Maike Janssen, Christina Schmidt, Stefanie Göllner, Christian Kleist, Fengbiao Zhou, Jens‐Ulrich Rahfeld, Tim Sauer, Michael Schmitt & Carsten Müller‐Tidow. (2021)
CD33
‐directed immunotherapy with third‐generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and
CD33
‐edited acute myeloid leukemia and hematopoietic stem and progenitor cells
. International Journal of Cancer 150:7, pages 1141-1155.
Crossref
Crossref
Wolf-Dieter Ludwig, Arnold Ganser & Georg Maschmeyer. 2022. Arzneiverordnungs-Report 2022. Arzneiverordnungs-Report 2022
85
151
.
Matthias Böhme & Sabine Kayser. (2021) Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia. Cancers 14:1, pages 105.
Crossref
Crossref
Felicitas Thol. (2021) What to use to treat AML: the role of emerging therapies. Hematology 2021:1, pages 16-23.
Crossref
Crossref
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, Martina Crysandt, Andreas Rank, Dirk Behringer, Lino Teichmann, Martin Görner, Ralf-Ulrich Trappe, Christoph Röllig, Stefan Krause, Maher Hanoun, Olaf Hopfer, Gerhard Held, Sebastian Buske, Lars Fransecky, Sabine Kayser, Christoph Schliemann, Kerstin Schaefer-Eckart, Yousef Al-Fareh, Jörg Schubert, Thomas Geer, Martin Kaufmann, Arne Brecht, Dirk Niemann, Meinhard Kieser, Martin Bornhäuser, Uwe Platzbecker, Hubert Serve, Claudia D. Baldus, Carsten Müller-Tidow & Richard F. Schlenk. (2021) Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. Trials 22:1.
Crossref
Crossref
Jessica A. Pollard, Erin Guest, Todd A. Alonzo, Robert B. Gerbing, Mike R. Loken, Lisa Eidenschink Brodersen, E. Anders Kolb, Richard Aplenc, Soheil Meshinchi, Susana C. Raimondi, Betsy Hirsch & Alan S. Gamis. (2021)
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
KMT2A
-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531
. Journal of Clinical Oncology 39:28, pages 3149-3160.
Crossref
Crossref
Michele Gottardi, Giorgia Simonetti, Alessandra Sperotto, Davide Nappi, Andrea Ghelli Luserna di Rorà, Antonella Padella, Marianna Norata, Maria Benedetta Giannini, Gerardo Musuraca, Francesco Lanza, Claudio Cerchione & Giovanni Martinelli. (2021) Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. Cancers 13:18, pages 4566.
Crossref
Crossref
Sonia Jaramillo & Richard F. Schlenk. (2021) Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?. Current Oncology Reports 23:9.
Crossref
Crossref
Katrin Teich, Julia Krzykalla, Silke Kapp-Schwoerer, Verena I. Gaidzik, Richard F. Schlenk, Peter Paschka, Daniela Weber, Walter Fiedler, Michael W.M. Kühn, Thomas Schroeder, Karin Mayer, Michael Lübbert, Dhanya Ramachandran, Axel Benner, Arnold Ganser, Hartmut Döhner, Michael Heuser, Konstanze Döhner & Felicitas Thol. (2021) Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica 106:11, pages 2986-2989.
Crossref
Crossref
Vasko Graklanov. 2021. Acute Leukemias. Acute Leukemias.
Wolf-Dieter Ludwig, Arnold Ganser & Georg Maschmeyer. 2021. Arzneiverordnungs-Report 2021. Arzneiverordnungs-Report 2021
579
638
.
Peiying Zuo. (2020) Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates. The AAPS Journal 22:5.
Crossref
Crossref
Nor A Muhamad, Nor S Mohd Dali, Aliza Mohd Yacob, Mohd S A Kassim, Noor A Lodz, S F Abdul Wahid & Tahir Aris. (2020) Effect and safety of gemtuzumab ozogamicin for the treatment of patients with acute myeloid leukaemia: a systematic review protocol. BMJ Open 10:6, pages e032503.
Crossref
Crossref
N. Jung, W.-J. Mayet, P.R. Mertens, J. Meyer (federführend)O.-A. Müller, M. Pfeifer, P. Schellinger, N. Weiss & C.-M. Wendtner. 2020. Rationelle Diagnostik und Therapie in der Inneren Medizin. Rationelle Diagnostik und Therapie in der Inneren Medizin
B-1
B30-3
.
Mehrdad Mahalleh, Mahsima Shabani, Elham Rayzan & Nima Rezaei. (2019) Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML. Immunotherapy 11:18, pages 1583-1600.
Crossref
Crossref
F. Thol. (2019) Was ist gesichert in der Therapie der akuten myeloischen Leukämie?What is recommended in the treatment of acute myeloid leukemia?. Der Internist 60:12, pages 1240-1250.
Crossref
Crossref
Xiao Huang, Hai Lin, Feng Huang, Yuning Xie, Ka Hong Wong, Xiaoyu Chen, Dongyue Wu, Aiping Lu & Zhijun Yang. (2019) Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia. Dose-Response 17:4, pages 155932581988704.
Crossref
Crossref
Jennifer Hibma & Beverly Knight. (2018) Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia. Clinical Pharmacokinetics 58:3, pages 335-347.
Crossref
Crossref
Susanne Hofmann, Maria-Luisa Schubert, Lei Wang, Bailin He, Brigitte Neuber, Peter Dreger, Carsten Müller-Tidow & Michael Schmitt. (2019) Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). Journal of Clinical Medicine 8:2, pages 200.
Crossref
Crossref
Richard F. Schlenk, Sonia Jaramillo & Carsten Müller-Tidow. (2018) What's new in consolidation therapy in AML?. Seminars in Hematology.
Crossref
Crossref
David J. H. F. Knapp, Colin A. Hammond, Tony Hui, Marijn T. J. van Loenhout, Fangwu Wang, Nima Aghaeepour, Paul H. Miller, Michelle Moksa, Gabrielle M. Rabu, Philip A. Beer, Davide Pellacani, R. Keith Humphries, Carl Hansen, Martin Hirst & Connie J. Eaves. (2018) Single-cell analysis identifies a CD33+ subset of human cord blood cells with high regenerative potential. Nature Cell Biology 20:6, pages 710-720.
Crossref
Crossref
Andrew Lucas, Lauren Price, Allison Schorzman, Mallory Storrie, Joseph Piscitelli, Juan Razo & William Zamboni. (2018) Factors Affecting the Pharmacology of Antibody–Drug Conjugates. Antibodies 7:1, pages 10.
Crossref
Crossref
Sabine Kayser & Mark J. Levis. (2017) Advances in targeted therapy for acute myeloid leukaemia. British Journal of Haematology 180:4, pages 484-500.
Crossref
Crossref
C D Godwin, R P Gale & R B Walter. (2017) Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia 31:9, pages 1855-1868.
Crossref
Crossref
Jatinder K. LambaLata ChauhanMiyoung ShinMichael R. LokenJessica A. PollardYi-Cheng WangRhonda E. RiesRichard AplencBetsy A. HirschSusana C. RaimondiRoland B. WalterIrwin D. BernsteinAlan S. GamisTodd A. AlonzoSoheil Meshinchi. (2017) CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531. Journal of Clinical Oncology 35:23, pages 2674-2682.
Crossref
Crossref
Jeremy A. O’Sullivan, Daniela J. Carroll & Bruce S. Bochner. (2017) Glycobiology of Eosinophilic Inflammation: Contributions of Siglecs, Glycans, and Other Glycan-Binding Proteins. Frontiers in Medicine 4.
Crossref
Crossref
Andrew T Lucas, Lauren SL Price, Allison Schorzman & William C Zamboni. (2017) Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents. Nanomedicine 12:16, pages 2021-2042.
Crossref
Crossref
M Wattad, D Weber, K Döhner, J Krauter, V I Gaidzik, P Paschka, M Heuser, F Thol, T Kindler, M Lübbert, H R Salih, A Kündgen, H-A Horst, P Brossart, K Götze, D Nachbaur, C-H Köhne, M Ringhoffer, G Wulf, G Held, H Salwender, A Benner, A Ganser, H Döhner & R F Schlenk. (2017) Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia 31:6, pages 1306-1313.
Crossref
Crossref
Gevorg Tamamyan, Tapan Kadia, Farhad Ravandi, Gautam Borthakur, Jorge Cortes, Elias Jabbour, Naval Daver, Maro Ohanian, Hagop Kantarjian & Marina Konopleva. (2017) Frontline treatment of acute myeloid leukemia in adults. Critical Reviews in Oncology/Hematology 110, pages 20-34.
Crossref
Crossref
Radoslav Mladenov, Dmitrij Hristodorov, Christian Cremer, Gerrit Gresch, Elena Grieger, Lea Schenke, Diana Klose, Manal Amoury, Mira Woitok, Edgar Jost, Tim H. Brümmendorf, Rolf Fendel, Rainer Fischer, Christoph Stein, Theo Thepen & Stefan Barth. (2016)
CD64-directed microtubule associated protein tau kills leukemic blasts
ex vivo
. Oncotarget 7:41, pages 67166-67174.
Crossref
Crossref
Jessica A. PollardMichael LokenRobert B. GerbingSusana C. RaimondiBetsy A. HirschRichard AplencIrwin D. BernsteinAlan S. GamisTodd A. AlonzoSoheil Meshinchi. (2016) CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531. Journal of Clinical Oncology 34:7, pages 747-755.
Crossref
Crossref
Alberto Visintin, Kelly Knowlton, Edyta Tyminski, Chi-Iou Lin, Xiang Zheng, Kimberly Marquette, Sadhana Jain, Lioudmila Tchistiakova, Dan Li, Christopher J. O'Donnell, Andreas Maderna, Xianjun Cao, Robert Dunn, William B. Snyder, Anson K. Abraham, Mauricio Leal, Shoba Shetty, Anthony Barry, Leigh Zawel, Anthony J. Coyle, Harold F. Dvorak & Shou-Ching Jaminet. (2015) Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. Molecular Cancer Therapeutics 14:8, pages 1868-1876.
Crossref
Crossref
Nestor Ramos, Clifton Mo, Judith Karp & Christopher Hourigan. (2015) Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. Journal of Clinical Medicine 4:4, pages 665-695.
Crossref
Crossref
Beata Piątkowska-Jakubas & Agnieszka Sporek-Kunicka. (2015) Ostre białaczki szpikowe – leczenie postaci nawrotowych i opornych. Acta Haematologica Polonica 46:2, pages 121-127.
Crossref
Crossref